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Abstract
Background: The rate of detection of HER-2/neu and CD117 (c-kit) overexpression in small cell lung cancer
(SCLC) has varied widely; between 5–35% and 21–70% respectively.
Methods: To evaluate the relationship between pesticide exposure and HER-2/neu and CD117 overexpression
in extensive stage SCLC (ESSCLC), we identified patients with ESSCLC and assessed pesticide exposure using a
predetermined questionnaire. An exposure index (hours/day × days/year × years) ≥  2400 hours was considered
as 'exposed.' HER-2/neu overexpression was evaluated on archival tissue using the DAKO Hercep test, and
CD117 testing was performed using immunohistochemistry (A4052 polyclonal antibody).
Results: 193 ESSCLC patients were identified. Pesticide exposure data could be obtained on 174 patients (84
females and 109 males) with a mean age of 68.5 years. 53/174 (30.4%) revealed HER-2/neu overexpression. 54/
174 (31.03%) specimens showed CD117 overexpression by IHC. On multivariate analysis, HER-2/neu
overexpression was associated with diminished survival (p < 0.001). In comparison, CD117 expression did not
have an adverse prognostic value (p = 0.025). 41/53 (77.4%) patients with HER-2/neu overexpression and 47/121
(38.8%) patients without overexpression had exposure to pesticides (odds ratio: 5.38; p < 0.01). Among the
cohort tested for CD117, 29/54 (53.7%) patients with CD117 overexpression and 59/120 (49.2%) patients
without CD117 overexpression had pesticide exposure (odds ratio: 1.18; p = 0.12).
Conclusion: Pesticide exposure affects HER-2/neu but not CD117 overexpression. Future studies are needed
to determine specific pesticide(s)/pesticide components that are responsible for HER-2/neu overexpression in
ESSCLC, and to validate our findings in other solid tumors that overexpress HER-2/neu.
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Introduction
Lung cancer is the most common malignancy both in
terms of incidence and mortality in the world. In 1999,
there were 1.04 million new cases (12.8%) and 921,000
deaths (17.8%) due to lung cancer all over the world [1].
It is expected that in 2004, there will be 173,770 new cases
of lung cancer diagnosed and 160,440 people will die of
lung cancer in the United States [2]. Small cell lung carci-
noma (SCLC), which comprises of 20% of lung cancer, is
characterized by a rapid growth rate and early metastases
[3,4]. Despite recent advances in therapy, the 2-year sur-
vival in limited stage small cell lung cancer is only 20–
30% [4], while the median survival in extensive stage
small cell lung cancer (ESSCLC) is less than a year (10.1
months) [5]. Given these dismal survival rates, it is imper-
ative that factors like biomarker profiles be evaluated in
an attempt to define survival characteristics.
We had previously described the overexpression of HER-
2/neu in approximately 29% of patients with ESSCLC. In
that same study, we also showed that this overexpression
led to a poorer outcome [6]. Micke et al found a definite
amplification of c-erbB-2 oncogene in 13% of patients
with SCLC; predominantly in ESSCLC. They thereby sug-
gested that HER-2/neu overexpression was more impor-
tant in advanced stages of the disease [7]. In contrast,
however, Schneider and associates found minimal or no
overexpression of HER-2/neu in four out of four cell lines
derived from small cell lung cancer [8]. Similarly, Bunn et
al evaluated eleven small cell lung cancer cell lines and
found no evidence of HER-2/neu overexpression [9].
In trying to explain these differences, we had hypothe-
sized in our previous report that the difference in the
methods used to detect HER-2/neu status (immunohisto-
chemistry vs. fluorescent in situ hybridization) and the
population studied (exclusively ESSCLC in our study),
could have been responsible for the difference found in
overexpression [6]. However, we were unable to defini-
tively explain the possible mechanisms responsible for
this high rate of HER-2/neu overexpression seen in our
study.
We have also demonstrated earlier that CD117 (c-kit)
overexpression occurred in about a third of patients with
ESSCLC [10]. The proto-oncogene c-kit encodes a trans-
membrane tyrosine kinase receptor (c-KIT/CD117)
related to the platelet-derived growth factor (PDGF)/col-
ony-stimulating factor-1 (CSF-1) (c-fms) receptor sub-
family [11]. CD117 is thought to play an important role
in hematopoiesis, spermatogenesis, melanogenesis and,
more recently, in carcinogenesis [12-14]. Overexpression
of CD117 has previously been documented in myeloid
leukemia, neuroblastoma, breast tumor, colon tumors,
gynecological tumors, testicular germ cell tumors and
SCLC [15-18].
Presented with two potential targets for therapy and/or
possible predictors of survival, the objective for our cur-
rent work was to undertake a retrospective comparison of
the degree of overexpression of HER-2/neu and CD117 in
ESSCLC samples, with a possible link to prior pesticide
exposure in our largely rural study population.
Materials and methods
After approval from the Institutional Review Board and
the Human Subjects Committee, a two-phase retrospec-
tive study was performed. The records of all patients with
a diagnosis of SCLC from January 1991 through April
2001 were reviewed. The data collected included the fol-
lowing variables regarding the patient's cancer history:
age, sex, socioeconomic status, family history of cancer (if
positive, type of cancer), smoking, performance score
(ECOG), stage of cancer, treatment modality/modalities
for SCLC, metastatic sites (other organs) involved, recur-
rent disease: symptoms at first recurrence age of recur-
rence, months from initial diagnosis and stage of disease
at recurrence, treatment received for the recurrence, cause
of death, other co-morbidities (non-malignant illnesses)
and associated malignancies (if any) in the same patient.
In addition, we conducted a population-based epidemio-
logic study in an effort to establish a relationship, if any,
between pesticide exposure, ESSCLC and HER-2/neu or
CD117 overexpression.
Pesticide risk assessment interviews were performed (by a
single member of the team for consistency) via telephone
on the basis of a pre-determined questionnaire. The ques-
tionnaire investigated occupations and hobbies with spe-
cial emphasis on:
(a) nature of exposure: insecticides and herbicides,
organic solvents (paints, varnishes, solvents and glues)
and petroleum products (diesels, petrol, oils, greases,
dyes, inks and colorings),
(b) type of exposure (preparation and/or spraying of pes-
ticide solutions, direct handling of solvents containing
materials or petroleum products),
(c) use of protective measures in the workplace (dissolv-
ing or spraying the pesticide with pressurized containers,
using glues or varnishes with adequate ventilation, etc.).
The subject was considered as 'non-exposed,' in the pres-
ence of these effective protection measures.
(d) duration of exposure. An exposure index was calcu-
lated for each interviewed subject according to the follow-
ing formula: hours/day × days/year × years [19]. PatientsJournal of Carcinogenesis 2005, 4:8 http://www.carcinogenesis.com/content/4/1/8
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with an exposure index >2400 h were considered as
'exposed', since previous reports have indicated that this
figure represents heavy exposure to genotoxic agents
[20,21].
HER-2/neu oncoprotein overexpression was assessed by
immunohistochemistry (IHC). Adequate pathologic sam-
ples were available on 193 subjects. IHC staining was car-
ried out on formalin fixed, paraffin-embedded material,
using the Hercep test developed by DAKO® Immunostain-
ing was classified as follows: 0 = no staining; 1+ = faint,
incomplete membranous pattern; 2+ = moderate, com-
plete membranous pattern; 3+ = strong membranous pat-
tern [22]. A trained pathologist (M.K.), who was blinded
from the clinical and exposure history of the patient, inter-
preted the IHC results. An IHC score of 2+ or greater was
considered as positive for HER-2/neu  overexpression
[23,24].
Detection of CD117 overexpression was assayed using an
IHC technique on archival paraffin-embedded tissue spec-
imens. Results were recorded on a semi-quantitative scale
to record the number of positive cells (10%, 10–50% and
>50%) and the intensity of reaction. CD117 status was
reported as positive if it was >10% and negative if it was
<10%. Immunohistochemical staining for c-kit (CD117)
was performed using a 1:250 dilution of the rabbit poly-
clonal antibody A4502 (IMPATH, Los Angeles, CA, USA)
with the EnVision detection system (IMPATH). An anti-
gen retrieval method was not utilized. Appropriate posi-
tive and negative controls were used throughout the
testing process. We used the A4502 antibody because it
has shown consistent performance with a low back-
ground, because it seems to be the most widely used c-kit
antibody, and because it is the antibody specified for
CD117 testing in the large cooperative clinical trials of
selective tyrosine kinase inhibitor STI-571. All interpreta-
tion of CD117 testing was performed by a single patholo-
gist (M.K.) who was blinded from the clinical data of
patients in our study population.
Statistical analysis was carried out using the chi-square test
to evaluate the association between pesticide exposure
and HER-2/neu vs. CD117 overexpression, and the Mann
Whitney U test to assess the impact of HER-2/neu and
CD117 overexpression on survival. Overall survival was
calculated from the date of diagnosis of lung carcinoma
by the Kaplan-Meier product limit method [25]. Logistic
regression analysis was performed to estimate the magni-
tude of the effect of pesticide exposure on HER-2/neu and
CD117 status. A multivariate analysis was performed to
analyze the prognostic impact of overexpression of either
oncoproteins. Statistical analysis was performed using
SPSS-10®
Results
Between 1991 and 2001, 223 patients with ESSCLC were
identified of whom 209 patients had complete records of
treatment. The most common chemotherapeutic regimen
involved using either cisplatin/carboplatin and etoposide
or carboplatin and paclitaxel. The most common second-
line agent used was docetaxel. 174 patients (98 males, 76
females) with a mean age of 68.5 years (range: 42–90
years) had adequate pathological specimens available for
definitive HER-2/neu  and CD117 testing by IHC. The
major symptoms at presentation and other relevant
demographic data of the study population are described
in Table-1. In our study, weight loss (52.8%) and cough
(59.0%) were the two most common presenting com-
plaints that showed a trend towards a decreased survival
(p = 0.03) in patients with ESSCLC.
Fifty-three (30.4%) of the 174 specimens revealed HER-2/
neu  overexpression by IHC while the remaining 121
(69.6%) did not (Table 1). After adjusting for age, smok-
ing, ECOG score and treatment, HER-2/neu overexpres-
sion was associated with a statistically significant
diminished survival (p < 0.001) [6]. Of the 53 patients
with HER-2/neu overexpression, we were able to ascertain
pesticide exposure in 41 patients (77.4%), while of the
121 without HER-2/neu overexpression, 47 (38.8%) had
a history of significant pesticide exposure, a statistically
significant difference (odds ratio: 5.38; p < 0.01, 95% CI:
2.5 – 11.2). After adjusting for age, gender and smoking
history, the odds ratio for developing a HER-2/neu posi-
tive tumor following pesticide exposure was still signifi-
cant (odds ratio: 15.7; 95% CI 5.3 – 46.6; p < 0.01). The
pesticide exposure occurred any time between 2 and 21
years prior to the diagnosis of the lung cancer. Patients
with an exposure index >2400 h were considered as
exposed although the length of exposure varied from
2400 to 7100 hrs.
As for CD117, of the 174 available specimens for review,
54 of 174 (31.0%) demonstrated IHC-verifiable CD117
overexpression, whereas 120 (69.0%) did not. Twenty-
nine of the 54 patients overexpressing CD117 (53.7%)
had evidence of pesticide exposure, whereas 59 of the 120
patients devoid of CD117 overexpression (49.2%) also
had pesticide exposure (odds ratio 1.18; p = 0.12) (Figure
1). Moreover, in contrast to HER-2/neu, CD117 overex-
pression carried with it no adverse prognostic significance
(p = 0.025).
Discussion
HER-2/neu (also known as c-erbB-2) oncogene is the sec-
ond member of the epidermal growth factor receptor fam-
ily. It is overexpressed in many different types of human
malignancies, notably, breast, lung, ovarian, gastric, pan-
creatic, colorectal, and cancers of the female genital tractJournal of Carcinogenesis 2005, 4:8 http://www.carcinogenesis.com/content/4/1/8
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[26-33]. HER-2/neu  overexpression seems to induce
chemoresistance in certain experimental conditions. Also,
HER-2/neu  overexpression has been associated with a
poor overall survival and the development of metastatic
phenotypes [26]. These findings suggest that HER-2/neu
may serve as an excellent target for developing targeted
anticancer agents, and indeed, the benefit of the mono-
clonal antibody against HER-2/neu  (trastuzumab) has
been demonstrated in the treatment of metastatic breast
carcinoma [34].
CD117 (c-kit) is a receptor-tyrosine kinase involved in
regulation of hematopoiesis as well as cell migration of
germ cells. Mutations in several key exons give rise to con-
stitutive activation of the receptor that ultimately is
responsible for the carcinogenesis of gastrointestinal stro-
mal tumors. This finding has in part led to the creation of
novel, tailored molecular therapy in the form of imatinib
mesylate (STI571) that has been successful where many
other anti-cancer therapies have failed [35].
Although animal studies demonstrate that many pesti-
cides are carcinogenic, (e.g., organochlorines, creosote,
and sulfallate) while others (notably, the organochlorines
DDT, chlordane, and lindane) are tumor promoters,
human data, however, are limited by the small number of
studies that evaluate individual pesticides [36]. In a case
control conducted to evaluate the hypothesis that past
exposure to the pesticide lead arsenate led to an excess
mortality from respiratory cancer, Wicklund et al found
that the presence, the intensity, nor the duration of expo-
sure to lead arsenate differed between cases and control
subjects [37]. McDuffie et al reported an absence of corre-
lation of lung cancer risk with occupational exposure to
any specific pesticide or pesticides grouped by chemical
composition [38]. In contrast, Blair et al studied the mor-
tality experience of a cohort of 3,827 white men licensed
to apply pesticides in Florida to investigate health effects
associated with chronic exposure to pesticides. They
found an increasing risk of lung cancer with number of
years licensed suggesting that some pesticides may be car-
cinogenic in humans [39]. Similarly, De Stefani et al
found that workers employed in the construction indus-
try, as well as those exposed to DDT may have an excess
risk of lung cancer [40]. Becher and associates also
showed an increased overall cancer mortality and mortal-
ity of respiratory cancer after long-term exposure to phe-
noxy herbicides and dioxins [41]. Pesatori and co-workers
showed that the risk of lung cancer was greater among
those who worked as pest control operators than non-pest
control workers [42].
In a predominantly agricultural state like North Dakota,
where farming is the main occupation, exposure to vari-
ous pesticides and herbicides is an everyday occurrence.
Tessier and Matsumara have shown that in the human
prostate cancer cell lines LNCaP and PC-3, erbB-2 kinase
was activated by pesticides of different chemical classes:
the organochlorine insecticides beta-hexa-chlorocy-
clohexane (beta-HCH), o,p'-dichlorodiphenyltrichlo-
roethane (o,p'-DDT), heptachlor epoxide, the pyrethroid
insecticide trans-permethrin, and the fungicide chloroth-
alonil [43]. Similarly, in another study, Enan and Matsu-
mara examined the effect of o,p'-DDT, the most estrogenic
Table 1: Demographic data and symptoms at initial presentation in relation to HER-2/neu and CD117 overexpression (n = 174)*.
HER-2/neu negative 
(n = 120)
HER-2/neu positive 
(n = 53)
CD117 negative 
(n = 119)
CD117 positive 
(n = 54)
Mean age at diagnosis (years): 65 66 63 65.5
Mean age at death (years): 67 68 67.5 67
Sex:
• Male (n = 98) 62 36 65 33
• Female (n = 76) 59 17 65 21
Performance score:
• Scores 0 – 2 (n = 102) 71 32 69 33
•  S c o r e s  3  –  4  ( n  =  7 2 ) 4 92 15 02 1
Most common symptoms*:
• Weight loss (n = 61) 47 14 44 17
•  C o u g h  ( n  =  5 3 ) 3 61 73 32 0
•  D y s p n e a  ( n  =  3 3 ) 2 672 76
* not all symptoms are included and some patients had more than one symptom at presentation.Journal of Carcinogenesis 2005, 4:8 http://www.carcinogenesis.com/content/4/1/8
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congener of the DDT family of chemicals and beta-HCH
on protein phosphorylation activities in MCF-7, a line
derived from human breast cancer cells. They found that
o,p'-DDT activated c-neu (HER-2/neu product protein) at
extremely low concentrations [44]. In a previous report,
we had shown that pesticide exposure was associated with
HER-2/neu overexpression [45].
With regards to CD117 overexpression, our prior work
has demonstrated that CD117 is overexpressed in about
30% of patients with ESSCLC [10]. Although the tech-
niques to ascertain CD117 testing were different, since our
reported prevalence of CD117 overexpression was differ-
ent from that described in previous studies [46,47], and
the fact that our study population was predominantly
rural and mostly consisted on of the farming community,
we decided to explore the link between CD117 overex-
pression and pesticide exposure. In addition, despite the
evidence on the role of pesticides in the pathogenesis of
lung cancer via potential avenues such as HER-2/neu, the
exact molecular role of pesticides on tumorigenesis in
humans is unclear at this time.
Although there are no studies in lung cancer, either in
patients or on cell lines demonstrating the biologic effects
of pesticides or their components, our results indicate that
pesticide exposure may indeed be related to HER-2/neu
but not CD117 overexpression in our select population
with ESSCLC. We found that patients with HER-2/neu
overexpression were significantly more likely to have been
exposed to pesticides (41/53; 77.4%), than those without
HER-2/neu overexpression (47/121; 38.8%) (Odds ratio:
Characteristics of CD117 overexpression and pesticide exposure in extensive stage small cell lung carcinoma (ESSCLC) Figure 1
Characteristics of CD117 overexpression and pesticide exposure in extensive stage small cell lung carcinoma (ESSCLC).Journal of Carcinogenesis 2005, 4:8 http://www.carcinogenesis.com/content/4/1/8
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5.38; p < 0.01). Our findings seem to agree with the field
cancerization theory of Gazdar which states that all or
much of the aerodigestive tract epithelium has been muta-
genized, perhaps as the result of exposure to carcinogens
leading to multiple molecular changes in individual cells
ultimately resulting in carcinogenesis [48]. Although
there is a relative dearth of clinical studies, experimental
studies using cancer cell lines revealed that HER-2/neu was
activated by various insecticides and fungicides of differ-
ent chemical classes [43,44]. However, whether this acti-
vation translates into clinical malignancy has not been
studied thus far. Our data suggest that the findings of
these experimental models may in fact be true in the car-
cinogenesis of small cell lung cancer. Interestingly, how-
ever, CD117 overexpression was not more prevalent in
patients with pesticide exposure (29/54; 53.7%) than
those lacking such exposure (59/120; 49.2%) (Odds ratio
1.18, p = 0.12).
Thus, the difference in our reported prevalence of CD117
overexpression in ESSCLC and previous studies possibly
was not due to pesticide exposure. Hibi et al. [47] reported
that over 60% of cases with SCLC overexpress CD117. In
another series, Sekido et al. [46] reported a higher inci-
dence of CD117 overexpression (81%) in SCLC. The rea-
son for the difference in our findings and the previous
reports may be attributable to the fact that our large study
included only patients with ESSCLC. Although the pres-
ence of CD117 does not carry definite prognostic value, it
is possible that overexpression may be preferentially
observed in patients with limited-stage SCLC. Earlier
reports used northern or western blotting techniques for
assessing CD117 expression; both of which are more sen-
sitive but less specific than IHC techniques [49,50]. This
difference in methodologies may also contribute to the
observed difference in CD117 overexpression.
We realize that as with most questionnaire-based studies,
a drawback of our study-design is the distinct possibility
of a recall bias among the case population. In addition, in
cases where the patient was deceased, the data was
obtained from the next of kin, who may or may not have
had detailed knowledge regarding pesticide exposure of
the subject in question. Interviewing technique plays a
central role in improving accuracy of the recall and is
under the control of the investigator [51]. We tried to min-
imize the effect of interviewing technique on the results
by having one single investigator conduct all the inter-
views. Also, we used prompted questions, rather than
open-ended question during the collection of exposure-
data as that has been shown to decrease recall bias [52].
Finally, another potential drawback to our study was the
fact that although we gathered enough data regarding the
extent of pesticide (insecticide/herbicide) exposure, while
implementing our questionnaire, we failed to investigate
the extent of exposure to specific pesticides/their compo-
nents. However, it is possible that the effect of individual
pesticides/pesticide components on HER-2/neu  overex-
pression may be better evaluated initially using SCLC cell
lines [44].
In conclusion, HER-2/neu  overexpression was seen in
slightly less than a third of patients with ESSCLC, and was
associated with decreased survival. Conversely, CD117
overexpression was noted in approximately half of ESS-
CLC patients, but was not correlated to prognosis. Our
data also suggest that pesticide exposure seems to be
related to HER-2/neu overexpression and may explain the
increased incidence of overexpression detected in our
study population. However CD117 expression appears to
be uninfluenced by pesticides, at least at the level of expo-
sure analyzed in our data. Future epidemiologic studies
are needed to validate our findings, and also to investigate
which pesticide(s)/pesticide components are actually
related to HER-2/neu overexpression, so that proper pre-
ventative measures may be adopted. Moreover, despite
the lack of an evident relation between pesticides, progno-
sis, and CD117, this cell marker may nonetheless provide
a valuable therapeutic target for select patients with ESS-
CLC as it does for certain patients with gastrointestinal
stromal tumors. Further studies are warranted to investi-
gate that possibility.
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